Search

Your search keyword '"White, Harvey D."' showing total 2,921 results

Search Constraints

Start Over You searched for: Author "White, Harvey D." Remove constraint Author: "White, Harvey D."
2,921 results on '"White, Harvey D."'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

4. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

7. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

12. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.

13. Myocardial Infarction in the ISCHEMIA Trial

15. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome

16. Impact of Complete Revascularization in the ISCHEMIA Trial

17. Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

19. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

22. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib

23. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

25. Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations

26. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.

27. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

29. Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies

30. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial

32. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial

33. Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals

36. Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

37. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

38. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

40. Abstract 10470: Projected Lifetime Benefits of Alirocumab in Patients After Acute Coronary Syndrome

42. Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

43. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

44. Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia

45. Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases

46. Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals

47. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits

50. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia

Catalog

Books, media, physical & digital resources